1 / 7

Amniotic membrane wound graft is effective for difficult-to-treat ulcerations

Dr. Laura Heath is the best Foot and Ankle surgeon in Phoenix, Arizona. Contact today!

lauraheathdpm
Télécharger la présentation

Amniotic membrane wound graft is effective for difficult-to-treat ulcerations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Amniotic membrane wound graft is effective for difficult-to-treat ulcerations

  2. Dehydrated human amnion/chorion membrane allografts appear to be a viable option for chronic lower extremity ulcerations refractory to standard of care therapy, researchers reported at Desert Foot 2014 in Phoenix, AZ. The mean number of weeks to wound closure was 5.89 in diabetics and 5.94 in non-diabetics.

  3. Dr. Laura Heath, with the Phoenix Veterans Administration Health System, presented results in 40 patients who were successfully treated with dehydrated human amnion/chorion membrane (dHACM) graft to full epithelialization. Study participants had undergone prior treatment for a chronic lower extremity foot ulcer that had failed to heal for at least 4 weeks after the start of treatment. Subjects underwent sharp debridement to remove non-viable tissue with a variety of adjunctive therapies including moist dressings, antibiotic ointments and negative-pressure therapy.

  4. In prior research, dHACM has been shown to contain growth factors that facilitate wound healing including PDGF-AA, PDGF-BB, bFGF, TGF-β1, EGF, VEGF, and PlGF, as well as anti-inflammatory interleukins (IL-1ra, IL-4, IL-10), and TIMP-1, TIMP-2, TIMP-4, which help regulate the matrix metalloproteinase activity, Dr. Heath pointed out. Follow-up in the study ranged from 4 to 108 weeks. The mean wound size at the time of the initial dHACM application was 2.79 cm2 in the 22 diabetic patients, 4.96 cm2 in the 18 non-diabetic patients and 3.36 cm2 in the combined groups.

  5. The mean number of dHACM applications was 3.36 in diabetics, 3.11 in non-diabetics and 3.25 in the combined groups. The mean number of weeks to wound closure was 5.89 in diabetics, 5.94 in non-diabetics, and 5.90 in the combined groups.

  6. dHACM is 'a useful wound healing modality' "Given the clinical risks and high cost associated with treating lower extremity ulcers, the development of treatment strategies to improve healing rates and reduce healing times is warranted," Dr. Heath said. "Overall, the results indicate that dHACM is a useful wound healing modality for recalcitrant lower limb ulcers," she added. Jill Stein is a Paris-based freelance medical writer.

  7. Contact Us: Dr. Laura Heath Podiatrist 202 E Earll Dr, Ste 360, Phoenix, AZ 85012 Phone No: 480-444-7477 CONSULTING ENQUIRIES: 515-669-9089

More Related